Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis.

Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister-Schultz A, Long N, White L, Carlos A, Henson RA, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Than H, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW.

Blood. 2019 Jul 31. pii: blood.2019000611. doi: 10.1182/blood.2019000611. [Epub ahead of print]

PMID:
31366621
2.

Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation.

Burslem GM, Schultz AR, Bondeson DP, Eide CA, Savage Stevens SL, Druker BJ, Crews CM.

Cancer Res. 2019 Jul 16. pii: canres.1236.2019. doi: 10.1158/0008-5472.CAN-19-1236. [Epub ahead of print]

PMID:
31311809
3.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia.

Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP; International CML Foundation Genomics Alliance.

Leukemia. 2019 Aug;33(8):1835-1850. doi: 10.1038/s41375-019-0512-y. Epub 2019 Jun 17. Review.

PMID:
31209280
4.

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Zhang H, Savage S, Schultz AR, Bottomly D, White L, Segerdell E, Wilmot B, McWeeney SK, Eide CA, Nechiporuk T, Carlos A, Henson R, Lin C, Searles R, Ho H, Lam YL, Sweat R, Follit C, Jain V, Lind E, Borthakur G, Garcia-Manero G, Ravandi F, Kantarjian HM, Cortes J, Collins R, Buelow DR, Baker SD, Druker BJ, Tyner JW.

Nat Commun. 2019 Jan 16;10(1):244. doi: 10.1038/s41467-018-08263-x.

5.

Functional genomic landscape of acute myeloid leukaemia.

Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblentz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, Jordan CT, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ.

Nature. 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17.

6.

Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.

Kurtz SE, Eide CA, Kaempf A, Mori M, Tognon CE, Borate U, Druker BJ, Tyner JW.

Leukemia. 2018 Sep;32(9):2025-2028. doi: 10.1038/s41375-018-0225-7. Epub 2018 Aug 6. No abstract available.

PMID:
30082821
7.

Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.

Jenkins C, Luty SB, Maxson JE, Eide CA, Abel ML, Togiai C, Nemecek ER, Bottomly D, McWeeney SK, Wilmot B, Loriaux M, Chang BH, Tyner JW.

Sci Signal. 2018 Jul 17;11(539). pii: eaao5617. doi: 10.1126/scisignal.aao5617.

8.

Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples.

Edwards V DK, Sweeney DT, Ho H, Eide CA, Rofelty A, Agarwal A, Liu SQ, Danilov AV, Lee P, Chantry D, McWeeney SK, Druker BJ, Tyner JW, Spurgeon SE, Loriaux MM.

Oncotarget. 2018 May 15;9(37):24576-24589. doi: 10.18632/oncotarget.25191. eCollection 2018 May 15.

9.

Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms.

Machado-Neto JA, Fenerich BA, Scopim-Ribeiro R, Eide CA, Coelho-Silva JL, Dechandt CRP, Fernandes JC, Rodrigues Alves APN, Scheucher PS, Simões BP, Alberici LC, de Figueiredo Pontes LL, Tognon CE, Druker BJ, Rego EM, Traina F.

Cell Death Dis. 2018 Feb 22;9(3):311. doi: 10.1038/s41419-017-0256-4.

10.

A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia.

Zabriskie MS, Antelope O, Verma AR, Draper LR, Eide CA, Pomicter AD, Tran TH, Druker BJ, Tyner JW, Miles RR, Graham JM, Hwang JY, Varley KE, Toydemir RM, Deininger MW, Raetz EA, O'Hare T.

Haematologica. 2018 Feb;103(2):e87-e91. doi: 10.3324/haematol.2017.165282. Epub 2017 Dec 28. No abstract available.

11.

CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy.

Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, Bolon DN.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11751-11756. doi: 10.1073/pnas.1708268114. Epub 2017 Oct 16.

12.

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.

Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, English I, Ho H, Pandya R, Bolosky WJ, Poon H, Deininger MW, Collins R, Swords RT, Watts J, Pollyea DA, Medeiros BC, Traer E, Tognon CE, Mori M, Druker BJ, Tyner JW.

Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):E7554-E7563. doi: 10.1073/pnas.1703094114. Epub 2017 Aug 7.

13.

Recurrent cyclin D2 mutations in myeloid neoplasms.

Khanna V, Eide CA, Tognon CE, Maxson JE, Wilmot B, Bottomly D, McWeeney S, Edwards V DK, Druker BJ, Tyner JW.

Leukemia. 2017 Sep;31(9):2005-2008. doi: 10.1038/leu.2017.195. Epub 2017 Jun 20. No abstract available.

14.

Understanding cancer from the stem cells up.

Eide CA, Druker BJ.

Nat Med. 2017 Jun 6;23(6):656-657. doi: 10.1038/nm.4353. No abstract available.

PMID:
28586338
15.

Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line.

Henderson JJ, Wagner JP, Hofmann NE, Eide CA, Cho YJ, Druker BJ, Davare MA.

Pediatr Blood Cancer. 2017 Oct;64(10). doi: 10.1002/pbc.26553. Epub 2017 Apr 14.

PMID:
28409891
16.

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, Pollyea DA, Deininger MW, Collins RH, Tyner JW, Druker BJ, Bagby GC, McWeeney SK, Agarwal A.

Cell Rep. 2017 Mar 28;18(13):3204-3218. doi: 10.1016/j.celrep.2017.03.018.

17.

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.

Pietarinen PO, Eide CA, Ayuda-Durán P, Potdar S, Kuusanmäki H, Andersson EI, Mpindi JP, Pemovska T, Kontro M, Heckman CA, Kallioniemi O, Wennerberg K, Hjorth-Hansen H, Druker BJ, Enserink JM, Tyner JW, Mustjoki S, Porkka K.

Oncotarget. 2017 Apr 4;8(14):22606-22615. doi: 10.18632/oncotarget.15146.

18.

Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Leonard JT, Rowley JS, Eide CA, Traer E, Hayes-Lattin B, Loriaux M, Spurgeon SE, Druker BJ, Tyner JW, Chang BH.

Sci Transl Med. 2016 Aug 31;8(354):354ra114. doi: 10.1126/scitranslmed.aaf5309.

PMID:
27582059
19.

IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.

de Melo Campos P, Machado-Neto JA, Eide CA, Savage SL, Scopim-Ribeiro R, da Silva Souza Duarte A, Favaro P, Lorand-Metze I, Costa FF, Tognon CE, Druker BJ, Olalla Saad ST, Traina F.

Oncotarget. 2016 Feb 9;7(6):6948-59. doi: 10.18632/oncotarget.6851.

20.

A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.

Drilon A, Somwar R, Wagner JP, Vellore NA, Eide CA, Zabriskie MS, Arcila ME, Hechtman JF, Wang L, Smith RS, Kris MG, Riely GJ, Druker BJ, O'Hare T, Ladanyi M, Davare MA.

Clin Cancer Res. 2016 May 15;22(10):2351-8. doi: 10.1158/1078-0432.CCR-15-2013. Epub 2015 Dec 16.

21.

Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.

Lue HW, Cole B, Rao SA, Podolak J, Van Gaest A, King C, Eide CA, Wilmot B, Xue C, Spellman PT, Heiser LM, Tyner JW, Thomas GV.

Oncotarget. 2015 Dec 29;6(42):44675-87. doi: 10.18632/oncotarget.5971.

22.

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

Zabriskie MS, Eide CA, Yan D, Vellore NA, Pomicter AD, Savage SL, Druker BJ, Deininger MW, O'Hare T.

Leukemia. 2016 Jun;30(6):1418-21. doi: 10.1038/leu.2015.318. Epub 2015 Nov 19. No abstract available.

23.

The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.

Maxson JE, Luty SB, MacManiman JD, Paik JC, Gotlib J, Greenberg P, Bahamadi S, Savage SL, Abel ML, Eide CA, Loriaux MM, Stevens EA, Tyner JW.

Clin Cancer Res. 2016 Feb 1;22(3):757-64. doi: 10.1158/1078-0432.CCR-14-3100. Epub 2015 Oct 16.

24.

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, O'Hare T, Druker BJ.

Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5381-90. doi: 10.1073/pnas.1515281112. Epub 2015 Sep 8.

25.

Therapeutically Targetable ALK Mutations in Leukemia.

Maxson JE, Davare MA, Luty SB, Eide CA, Chang BH, Loriaux MM, Tognon CE, Bottomly D, Wilmot B, McWeeney SK, Druker BJ, Tyner JW.

Cancer Res. 2015 Jun 1;75(11):2146-50. doi: 10.1158/0008-5472.CAN-14-1576.

26.

Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.

Eide CA, O'Hare T.

Curr Hematol Malig Rep. 2015 Jun;10(2):158-66. doi: 10.1007/s11899-015-0248-3. Review.

27.

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.

Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, Roberts JM, Druker BJ, Deininger MW.

Blood. 2014 Nov 20;124(22):3260-73. doi: 10.1182/blood-2013-04-497040. Epub 2014 Oct 7.

28.

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR.

Sci Transl Med. 2014 Sep 3;6(252):252ra121. doi: 10.1126/scitranslmed.3009073.

29.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernández-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, O'Hare T.

Cancer Cell. 2014 Sep 8;26(3):428-442. doi: 10.1016/j.ccr.2014.07.006. Epub 2014 Aug 14.

30.

Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.

Agarwal A, MacKenzie RJ, Eide CA, Davare MA, Watanabe-Smith K, Tognon CE, Mongoue-Tchokote S, Park B, Braziel RM, Tyner JW, Druker BJ.

Oncogene. 2015 Jun 4;34(23):2991-9. doi: 10.1038/onc.2014.243. Epub 2014 Aug 11.

31.

Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.

Agarwal A, MacKenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, Vitek MP, Odero MD, Christensen DJ, Druker BJ.

Clin Cancer Res. 2014 Apr 15;20(8):2092-103. doi: 10.1158/1078-0432.CCR-13-2575. Epub 2014 Jan 16.

32.

Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.

Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ.

Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19519-24. doi: 10.1073/pnas.1319583110. Epub 2013 Nov 11.

33.

Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.

Vainstein V, Eide CA, O'Hare T, Shukron O, Druker BJ.

Blood. 2013 Nov 7;122(19):3331-4. doi: 10.1182/blood-2012-08-452409. Epub 2013 Sep 23.

34.

Kinase inhibitor therapy in CML: it's what's inside that counts.

Eide CA, Druker BJ, O'Hare T.

Oncotarget. 2013 Sep;4(9):1332-3. No abstract available.

35.

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.

Cancer Res. 2013 Sep 15;73(18):5775-86. doi: 10.1158/0008-5472.CAN-13-1318. Epub 2013 Jul 25.

36.

Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.

Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW.

N Engl J Med. 2013 May 9;368(19):1781-90. doi: 10.1056/NEJMoa1214514.

37.

Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.

O'Hare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, Tyner JW, Deininger MW, Druker BJ.

Cancer Res. 2013 Jun 1;73(11):3356-70. doi: 10.1158/0008-5472.CAN-12-3904. Epub 2013 Apr 10.

38.

HitWalker: variant prioritization for personalized functional cancer genomics.

Bottomly D, Wilmot B, Tyner JW, Eide CA, Loriaux MM, Druker BJ, McWeeney SK.

Bioinformatics. 2013 Feb 15;29(4):509-10. doi: 10.1093/bioinformatics/btt003. Epub 2013 Jan 9.

39.

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, O'Hare T, Deininger MW.

Blood. 2013 Jan 17;121(3):489-98. doi: 10.1182/blood-2012-05-431379. Epub 2012 Dec 5.

40.

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R.

Cancer Cell. 2011 Dec 13;20(6):715-27. doi: 10.1016/j.ccr.2011.11.004.

41.

The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

O'Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM, Toplin J, Wong S, Deininger MW, Druker BJ.

Blood. 2011 Nov 10;118(19):5250-4. doi: 10.1182/blood-2011-05-349191. Epub 2011 Sep 8.

42.

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ.

Cancer Res. 2011 May 1;71(9):3189-95. doi: 10.1158/0008-5472.CAN-10-3224. Epub 2011 Apr 19.

43.

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.

O'Hare T, Deininger MW, Eide CA, Clackson T, Druker BJ.

Clin Cancer Res. 2011 Jan 15;17(2):212-21. doi: 10.1158/1078-0432.CCR-09-3314. Epub 2010 Nov 22.

44.

Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.

Gregory MA, Phang TL, Neviani P, Alvarez-Calderon F, Eide CA, O'Hare T, Zaberezhnyy V, Williams RT, Druker BJ, Perrotti D, Degregori J.

Cancer Cell. 2010 Jul 13;18(1):74-87. doi: 10.1016/j.ccr.2010.04.025.

45.

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.

O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T.

Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028.

46.

The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis.

Demehri S, O'Hare T, Eide CA, Smith CA, Tyner JW, Druker BJ, Deininger MW.

Leukemia. 2010 Jan;24(1):226-9. doi: 10.1038/leu.2009.196. Epub 2009 Sep 17. No abstract available.

PMID:
19759561
47.

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.

Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ, Deininger MW.

Blood. 2009 Oct 15;114(16):3459-63. doi: 10.1182/blood-2007-10-113969. Epub 2009 Aug 25.

48.

New strategies for the first-line treatment of chronic myeloid leukemia: can resistance be avoided?

Snead JL, O'Hare T, Eide CA, Deininger MW.

Clin Lymphoma Myeloma. 2008 Mar;8 Suppl 3:S107-17. doi: 10.3816/CLM.2008.s.006. Review.

PMID:
19254881
49.

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Tyner JW, Erickson H, Deininger MW, Willis SG, Eide CA, Levine RL, Heinrich MC, Gattermann N, Gilliland DG, Druker BJ, Loriaux MM.

Blood. 2009 Feb 19;113(8):1749-55. doi: 10.1182/blood-2008-04-152157. Epub 2008 Dec 15.

50.

Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate.

Chou CJ, O'Hare T, Lefebvre S, Alvarez D, Tyner JW, Eide CA, Druker BJ, Gottesfeld JM.

PLoS One. 2008;3(10):e3593. doi: 10.1371/journal.pone.0003593. Epub 2008 Oct 31.

Supplemental Content

Support Center